Paracetamol (acetaminophen) esters of some non-steroidal anti-inflammatory carboxylic acids as mutual prodrugs with improved therapeutic index
- 298 Downloads
Paracetamol (acetaminophen) esters [4a-f] of some acidic NSAIDs were synthesized and evaluated as mutual prodrug forms with the aim of improving the therapeutic index through prevention of the gastrointestinal toxicity. The structures of the synthesized esters were confirmed by IR and 1H-NMR spectroscopy and their purity was established by elemental analyses and TLC. In-vitro stability studies revealed that the synthesized ester prodrugs 4a-f are sufficiently chemically stable in non-enzymatic simulated gastric fluid (hydrochloric acid buffer of pH 1.3 (t 1/2 ∼ 15–45 h)) and in phosphate buffer of pH 7.4 (t 1/2 ∼ 4–40 h). In 80% human plasma and 10% rat liver homogenate, the mutual prodrugs were found to be susceptible to enzymatic hydrolysis releasing the corresponding NSAID and paracetamol at relatively faster rates (t 1/2 ≈ 15–385 min and 1–140 min, respectively). Calculated log P values indicated that the prodrugs 4a-f are more lipophilic than the parent drugs.
In-vivo experiments in rabbits showed higher plasma levels of ibuprofen after oral administration of its ester prodrug 4b compared with those resulting from an equivalent amount of the corresponding physical mixture. Moreover, significant improvement in latency of pain threshold in mice has been observed up to 4 h after po administration of 0.02 mmol/kg of the prodrugs, compared with the corresponding physical mixtures. Gross observations and scanning electromicrographs of the stomach showed that the prodrugs induced very little irritancy in the gastric mucosa of mice after oral administration for 4 days. These results suggest that the synthesized mutual ester prodrugs were characterized by a better therapeutic index than the parent drugs.
Keywordsparacetamol (acetaminophen) NSAIDs chemical and enzymatic stability ulcerogenicity pain threshold latency prodrugs
- 3.Jones G. Decreased toxicity and adverse reactions via prodrugs. In: Bundgaard H, ed. Design of Prodrugs. Amsterdam: Elsevier; 1985:199–241.Google Scholar
- 7.Vermeulen NPE, Straat RV, TeKoppele JM et al. Molecular mechanisms in toxicology and drug design. In: Classen V, ed. Trends in Drug Research, Vol. 13. Amsterdam: Elsevier; 1990:253–71.Google Scholar
- 10.Omar FA. Cyclic amide derivatives as potential prodrugs. Synthesis and evaluation of N-hydroxymethylphthalimide esters of some NSAI carboxylic acid drugs. Eur J Med Chem. 1998;33 [in press].Google Scholar
- 14.Shen TY. Non steroidal antiinflammatory agents. In: Wolf EM, ed. Burger’s Medicinal Chemistry, 4th edn, Part III. New York: John-Willey and Sons; 1980:1228.Google Scholar
- 20.Moffat AC, ed. Clark’s Isolation and Identification of Drugs. London: Pharmaceutical Press; 1986.Google Scholar